SV2010003529A - Composicion de zibotentan que contiene manitol y/o celulosa microcristalina - Google Patents

Composicion de zibotentan que contiene manitol y/o celulosa microcristalina

Info

Publication number
SV2010003529A
SV2010003529A SV2010003529A SV2010003529A SV2010003529A SV 2010003529 A SV2010003529 A SV 2010003529A SV 2010003529 A SV2010003529 A SV 2010003529A SV 2010003529 A SV2010003529 A SV 2010003529A SV 2010003529 A SV2010003529 A SV 2010003529A
Authority
SV
El Salvador
Prior art keywords
zibotentan
manitol
microcrystalline cellulose
composition
methylpirazin
Prior art date
Application number
SV2010003529A
Other languages
English (en)
Inventor
John David Blyth
Andrew John Day
Kieran James Lennon
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40534840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2010003529(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SV2010003529A publication Critical patent/SV2010003529A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE DESCRIBE UNA COMPOSICIÓN FARMACÉUTICA QUE CONTIENE N-(3-METOXI-5-METILPIRAZIN-2-IL)-2-(4-[1,3,4-OXADIAZOL-2-IL]FENIL)PIRIDIN-3-SULFONAMIDA (ES DECIR, ZIBOTENTAN O ZD4054) CON MANITOL Y/O CELULOSA MICROCRISTALINA
SV2010003529A 2007-10-12 2010-04-12 Composicion de zibotentan que contiene manitol y/o celulosa microcristalina SV2010003529A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97973607P 2007-10-12 2007-10-12
US8911808P 2008-08-15 2008-08-15

Publications (1)

Publication Number Publication Date
SV2010003529A true SV2010003529A (es) 2010-09-13

Family

ID=40534840

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2010003529A SV2010003529A (es) 2007-10-12 2010-04-12 Composicion de zibotentan que contiene manitol y/o celulosa microcristalina

Country Status (35)

Country Link
US (2) US8168221B2 (es)
EP (2) EP2433620A1 (es)
JP (1) JP2011500548A (es)
KR (1) KR20100099113A (es)
CN (1) CN101896210A (es)
AR (1) AR068845A1 (es)
AT (1) ATE536893T1 (es)
AU (1) AU2008309385B2 (es)
BR (1) BRPI0818323A2 (es)
CA (1) CA2701385A1 (es)
CL (1) CL2008003022A1 (es)
CO (1) CO6270344A2 (es)
CR (1) CR11363A (es)
CU (1) CU20100064A7 (es)
CY (1) CY1112433T1 (es)
DK (1) DK2209501T3 (es)
DO (1) DOP2010000105A (es)
EA (1) EA201000545A1 (es)
ES (1) ES2377426T3 (es)
HK (1) HK1143095A1 (es)
HR (1) HRP20120085T1 (es)
IL (1) IL204953A0 (es)
MX (1) MX2010003989A (es)
NI (1) NI201000052A (es)
NZ (1) NZ585310A (es)
PE (1) PE20091032A1 (es)
PL (1) PL2209501T3 (es)
PT (1) PT2209501E (es)
SG (1) SG182138A1 (es)
SI (1) SI2209501T1 (es)
SV (1) SV2010003529A (es)
TW (1) TW200924768A (es)
UY (1) UY31385A1 (es)
WO (1) WO2009047565A2 (es)
ZA (1) ZA201002477B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006527200A (ja) 2003-06-06 2006-11-30 ファイブロゲン インコーポレイティッド 窒素含有ヘテロアリール化合物および内因性エリトロポエチンを増加させる際のそれらの使用方法
CA2701385A1 (en) 2007-10-12 2009-04-16 Astrazeneca Ab Composition 064
CN101822796B (zh) * 2010-03-17 2012-01-04 山西仟源制药有限公司 一种银冰含片及制备方法和应用
EP2568973A2 (en) * 2010-05-11 2013-03-20 Sensient Colors LLC Film coating composition and methods of making and using the same
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
MX369549B (es) * 2012-04-27 2019-11-12 Merck Patent Gmbh Un proceso para la fabricación de núcleos de tabletas duros con recubrimiento.
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
RS57795B1 (sr) 2012-07-16 2018-12-31 Fibrogen Inc Kristalni oblici inhibitora prolil hidroksilaze
KR20210104173A (ko) 2013-06-06 2021-08-24 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형
WO2021200767A1 (ja) * 2020-03-31 2021-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 錠剤、医薬及びそれらの製造方法並びにキット

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674794A (en) * 1970-03-18 1972-07-04 Ciba Geigy Corp Certain-3-pyridine-sulfonamide derivatives
UA58494C2 (uk) 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
CA2281090C (en) * 1997-04-28 2005-06-07 Texas Biotechnology Corporation Sulfonamide compounds and salts for treatment of endothelin-mediated disorders
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
WO2000078292A1 (fr) * 1999-06-18 2000-12-28 Takeda Chemical Industries, Ltd. Preparations solides a desintegration rapide
JP2001058944A (ja) * 1999-06-18 2001-03-06 Takeda Chem Ind Ltd 速崩壊性固形製剤
CN1615135A (zh) * 2001-11-13 2005-05-11 法马西亚公司 磺酰胺前药如帕瑞考昔的口服剂型
GB0219660D0 (en) * 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
EP1551401A4 (en) * 2002-09-20 2006-03-22 Merck & Co Inc MANNITOL FORMULATION FOR AN INTEGRIN RECEPTOR ANTAGONIST
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
CN101032464A (zh) * 2007-04-01 2007-09-12 杨喜鸿 含有利莫那班和聚乙烯吡咯烷酮的组合物、固体分散体及其制备和药物应用
CA2701385A1 (en) 2007-10-12 2009-04-16 Astrazeneca Ab Composition 064

Also Published As

Publication number Publication date
JP2011500548A (ja) 2011-01-06
HRP20120085T1 (hr) 2012-02-29
CY1112433T1 (el) 2015-12-09
DOP2010000105A (es) 2010-08-15
DK2209501T3 (da) 2012-02-27
EP2433620A1 (en) 2012-03-28
AU2008309385A1 (en) 2009-04-16
CR11363A (es) 2010-07-14
WO2009047565A3 (en) 2009-11-26
BRPI0818323A2 (pt) 2017-05-16
UY31385A1 (es) 2009-05-29
MX2010003989A (es) 2010-04-27
EP2209501A2 (en) 2010-07-28
PE20091032A1 (es) 2009-08-15
IL204953A0 (en) 2010-11-30
ES2377426T3 (es) 2012-03-27
SI2209501T1 (sl) 2012-03-30
KR20100099113A (ko) 2010-09-10
EA201000545A1 (ru) 2010-10-29
US8168221B2 (en) 2012-05-01
SG182138A1 (en) 2012-07-30
CO6270344A2 (es) 2011-04-20
NZ585310A (en) 2012-02-24
CA2701385A1 (en) 2009-04-16
WO2009047565A2 (en) 2009-04-16
PL2209501T3 (pl) 2012-03-30
AU2008309385B2 (en) 2011-10-20
NI201000052A (es) 2011-03-24
PT2209501E (pt) 2012-02-03
ATE536893T1 (de) 2011-12-15
TW200924768A (en) 2009-06-16
US20090099203A1 (en) 2009-04-16
CU20100064A7 (es) 2011-10-05
CN101896210A (zh) 2010-11-24
CL2008003022A1 (es) 2010-07-23
AR068845A1 (es) 2009-12-09
HK1143095A1 (en) 2010-12-24
US20120177705A1 (en) 2012-07-12
EP2209501B1 (en) 2011-12-14
ZA201002477B (en) 2010-12-29

Similar Documents

Publication Publication Date Title
SV2010003529A (es) Composicion de zibotentan que contiene manitol y/o celulosa microcristalina
BRPI0815048A2 (pt) derivado de fenóxi-pirrolidinas e uso e composições do mesmo
CL2007001391A1 (es) Compuestos derivados de pirrolidinas sustituidas, inhibidores del factor xa y/o inhibidores sobre la serina proteasa; composicion farmaceutica que comprende a dichos compuestos; proedimiento para preparar la composicon farmaceutica; y uso de los compuestos preparar un medicamneto con un efecto antitrombotico
BRPI0809977A2 (pt) Uso de um composto, compostos e composição farmacêutica que o contém
CL2008002998A1 (es) Compuestos derivados de piperazina-1-carboxamida, inhibidor de faah; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor inflamatorio o neuropatico, ansiedad y depresion.
CL2007001689A1 (es) Formas cristalinas sustancialmente puras de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida; composicion farmaceutica, util para tratar una enfermedad que responde a una inhibicion de la actividad de cinasa de prot
BRPI1016219B8 (pt) composto indazol substituído com oxazol, e, composição farmacêutica
CL2011001224A1 (es) Compuestos derivados de benzofurano-3-carboxamida; composicion farmaceutica que los comprende; y su uso en tratamiento del virus de la hepatitis c.
BRPI0820171B8 (pt) compostos de carboxamida, sulfonamida e amina para distúrbios metabólicos, composição farmacêutica, e, uso dos mesmos
CL2008000873A1 (es) Compuestos derivados de pirrolidin amidas; composicion farmaceutica que comprende dichos compuestos; y su uso para tratar trombosis.
UY29007A1 (es) Derivados de 2-carbamida-4-feniltiazol, su preparacinn, y su aplicacinn en terapcutica
DK2027096T3 (da) Substituerede arylimidazoloner og -triazoloner som inhibitorer for vasopressinreceptorerne
PE20100083A1 (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
CL2008000134A1 (es) Compuesto 5-[4-(2 metil fenil)-3-hidroxi-4h-[1,2,4] triazol-5-il]-2,4-dihidroxi n metil n butil benzamida; composicion farmaceutica que contiene a dicho compuesto; kit farmaceutico que contiene a dicho compuesto; y su uso para tratar cancer, enfermed
CL2007000918A1 (es) Compuestos derivados de enfumafungina, inhibidores de (1,3)-beta-d-glucanosintetasa; composicion farmaceutica; y uso para tratar una infeccion fungica.
CL2011000820A1 (es) Composicion antimicrobiana sinergica que comprende tebuconazol y una mezcla de 5-cloro-2-metil-4-isotiazolin-3-ona y 2-metil-4-isotiazolin-3-ona (div. sol.1421-06)
FR2902647B1 (fr) Compositions de maquillage des matieres keratiniques
ATE466838T1 (de) Sulfonamid-derivate als lebercarnitin-palmitoyl- transferase-hemmer
CL2008002041A1 (es) Compuestos derivados de piperidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar ansiedad.
UY30142A1 (es) Composiciones antimicoticas ramnolipidas y metodos de uso relacionados
UY30144A1 (es) Composiciones de ramnolipidos y metodos de uso relacionados
NO20085317L (no) Imidazoazepinonforbindelser
BRPI0720684A2 (pt) composto, medicamento, composição farmacêutica que contém e uso do composto
CL2008003358A1 (es) Hidratos cristalinos de n-(4((2s,3r)-3-((s)-3-(4-fluorofenil)-3-hidroxipropil)-2-(4-metoxifenil)4-oxoazetidin-1-il)bencil)-n-((2s,3r,4r,5r)-2,3,4,5,6-pentahidroxihexil)dodecandiamida; procedimiento de preparacion de dicho compuesto; composiicon farmaceutica que lo comprende; y uso para tratar trastornos del metabolismo de lipidos.
UY31900A (es) Formas solidas de ( 1r, 2s, 3r)-1-(2-(usoxazol-3-il)-1h-imidazol-4-il)butano-1, 2, 3, 4-tetraol y metodos de uso.

Legal Events

Date Code Title Description
FD Lapse